Abstract
The melanocortin pathway consists of endogenous agonists, antagonists, G-protein coupled receptors (GPCRs), and auxiliary proteins. This pathway has been identified to participate physiologically in numerous biological pathways including energy homeostasis, pigmentation, sexual function, inflammation, cardiovascular function, adrenal function, sebaceous gland lipid production, just to list a few. During this past decade, a clear link between the melanocortin-4 receptor (MC4R) and obesity, in both mice and humans via the regulation of food intake and energy homeostasis, has made this pathway the target of many academic and industrial research endeavors in attempts to develop potent and selective MC4R small molecules as anti-obesity therapeutic agents. Herein, we attempt to summarize the known proteins that constitute the melanocortin system and discuss advances in peptide and non-peptide drug discovery.
Keywords: proopiomelanocortin, melanocortin receptor agonists, msh, acth, corticotrophin releasing hormone, heparan sulfate proteoglycans
Current Pharmaceutical Design
Title: Progress in the Development of Melanocortin Receptor Selective Ligands
Volume: 10 Issue: 28
Author(s): Boman G. Irani, Jerry R. Holder, Aleksandar Todorovic, Andrzej M. Wilczynski, Christine G. Joseph, Krista R. Wilson and Carrie Haskell-Luevano
Affiliation:
Keywords: proopiomelanocortin, melanocortin receptor agonists, msh, acth, corticotrophin releasing hormone, heparan sulfate proteoglycans
Abstract: The melanocortin pathway consists of endogenous agonists, antagonists, G-protein coupled receptors (GPCRs), and auxiliary proteins. This pathway has been identified to participate physiologically in numerous biological pathways including energy homeostasis, pigmentation, sexual function, inflammation, cardiovascular function, adrenal function, sebaceous gland lipid production, just to list a few. During this past decade, a clear link between the melanocortin-4 receptor (MC4R) and obesity, in both mice and humans via the regulation of food intake and energy homeostasis, has made this pathway the target of many academic and industrial research endeavors in attempts to develop potent and selective MC4R small molecules as anti-obesity therapeutic agents. Herein, we attempt to summarize the known proteins that constitute the melanocortin system and discuss advances in peptide and non-peptide drug discovery.
Export Options
About this article
Cite this article as:
Irani G. Boman, Holder R. Jerry, Todorovic Aleksandar, Wilczynski M. Andrzej, Joseph G. Christine, Wilson R. Krista and Haskell-Luevano Carrie, Progress in the Development of Melanocortin Receptor Selective Ligands, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382891
DOI https://dx.doi.org/10.2174/1381612043382891 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris
Current Drug Safety Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Antiproliferative Effects of Nerium oleander Leaves and Their Cardiac Glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
Current Traditional Medicine QT Prolongation and Safety in the Indian Population
Current Drug Safety The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery Prognostic Impact of Red Cell Distribution Width on the Development of Contrast-Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Current Cardiology Reviews α2-Antiplasmin on Cardiovascular Diseases
Current Pharmaceutical Design CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery New Antidiabetic Therapies: A Paradigm Shift in Type 2 Diabetes Management
Current Pharmaceutical Design